 Maura Gasparetto
Concepts (225)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aldehyde Dehydrogenase | 8 | 2017 | 100 | 2.140 |
Why?
| | Leukemia, Myeloid, Acute | 10 | 2025 | 646 | 1.630 |
Why?
| | Hematopoietic Stem Cells | 8 | 2017 | 411 | 1.330 |
Why?
| | Cytarabine | 1 | 2019 | 64 | 0.590 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2019 | 93 | 0.580 |
Why?
| | Cation Transport Proteins | 1 | 2019 | 109 | 0.560 |
Why?
| | Hematopoiesis | 3 | 2015 | 194 | 0.460 |
Why?
| | Flow Cytometry | 8 | 2012 | 1197 | 0.460 |
Why?
| | Hematologic Neoplasms | 1 | 2017 | 159 | 0.460 |
Why?
| | Cell Proliferation | 4 | 2019 | 2504 | 0.450 |
Why?
| | Biomarkers, Tumor | 2 | 2019 | 1251 | 0.450 |
Why?
| | Neoplastic Stem Cells | 5 | 2025 | 400 | 0.440 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | 2025 | 125 | 0.430 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 1040 | 0.420 |
Why?
| | Antigens, Differentiation | 2 | 2012 | 82 | 0.390 |
Why?
| | G1 Phase | 2 | 2012 | 72 | 0.380 |
Why?
| | Adult Stem Cells | 1 | 2012 | 40 | 0.370 |
Why?
| | Graft Survival | 1 | 2012 | 499 | 0.310 |
Why?
| | Hematopoietic Stem Cell Transplantation | 6 | 2012 | 668 | 0.310 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 3 | 2025 | 238 | 0.290 |
Why?
| | Cell Self Renewal | 2 | 2019 | 54 | 0.280 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2025 | 1787 | 0.260 |
Why?
| | Azacitidine | 2 | 2025 | 150 | 0.260 |
Why?
| | Sulfonamides | 3 | 2025 | 520 | 0.250 |
Why?
| | B-Lymphocytes | 1 | 2011 | 858 | 0.250 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2017 | 333 | 0.230 |
Why?
| | Retinal Dehydrogenase | 2 | 2017 | 29 | 0.220 |
Why?
| | Antineoplastic Agents | 6 | 2017 | 2166 | 0.220 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2004 | 193 | 0.210 |
Why?
| | Fetal Blood | 2 | 2017 | 341 | 0.200 |
Why?
| | Mice | 13 | 2025 | 18048 | 0.200 |
Why?
| | Prognosis | 4 | 2025 | 4073 | 0.200 |
Why?
| | Lymphoma | 1 | 2004 | 228 | 0.190 |
Why?
| | Reactive Oxygen Species | 2 | 2017 | 630 | 0.180 |
Why?
| | Cell Separation | 5 | 2011 | 317 | 0.180 |
Why?
| | Cells, Cultured | 5 | 2019 | 4208 | 0.170 |
Why?
| | Drug Resistance, Neoplasm | 5 | 2025 | 830 | 0.170 |
Why?
| | Animals | 17 | 2025 | 37657 | 0.170 |
Why?
| | Nuclear Pore Complex Proteins | 2 | 2011 | 35 | 0.150 |
Why?
| | Leukopoiesis | 1 | 2019 | 11 | 0.150 |
Why?
| | Myeloid Progenitor Cells | 1 | 2019 | 16 | 0.150 |
Why?
| | NADPH Oxidase 2 | 1 | 2019 | 41 | 0.150 |
Why?
| | Cytogenetic Analysis | 1 | 2019 | 34 | 0.150 |
Why?
| | Antibodies, Monoclonal | 3 | 2007 | 1448 | 0.150 |
Why?
| | Protein Kinase Inhibitors | 1 | 2025 | 914 | 0.150 |
Why?
| | DNA Damage | 2 | 2011 | 427 | 0.150 |
Why?
| | Decision Support Systems, Clinical | 1 | 2022 | 258 | 0.140 |
Why?
| | Tumor Cells, Cultured | 2 | 2019 | 959 | 0.140 |
Why?
| | Blast Crisis | 3 | 2025 | 33 | 0.140 |
Why?
| | Fusion Proteins, bcr-abl | 3 | 2012 | 70 | 0.140 |
Why?
| | Bone Marrow Cells | 2 | 2017 | 325 | 0.140 |
Why?
| | Blood Cells | 1 | 2017 | 39 | 0.130 |
Why?
| | Arsenicals | 1 | 2017 | 30 | 0.130 |
Why?
| | Oxides | 1 | 2017 | 49 | 0.130 |
Why?
| | Leukemia | 1 | 2019 | 244 | 0.130 |
Why?
| | Recombinant Fusion Proteins | 2 | 2011 | 672 | 0.130 |
Why?
| | Heterografts | 1 | 2017 | 134 | 0.130 |
Why?
| | Cyclophosphamide | 1 | 2017 | 256 | 0.130 |
Why?
| | Isoenzymes | 1 | 2017 | 302 | 0.130 |
Why?
| | Mice, Inbred C57BL | 8 | 2019 | 5887 | 0.120 |
Why?
| | Enzyme Inhibitors | 2 | 2013 | 854 | 0.120 |
Why?
| | Homeodomain Proteins | 2 | 2011 | 511 | 0.120 |
Why?
| | Cell Cycle | 2 | 2011 | 597 | 0.120 |
Why?
| | Animals, Congenic | 2 | 2011 | 9 | 0.110 |
Why?
| | Radiation Chimera | 2 | 2011 | 28 | 0.110 |
Why?
| | Survival Rate | 1 | 2019 | 1970 | 0.110 |
Why?
| | Gene Deletion | 2 | 2012 | 388 | 0.110 |
Why?
| | Benzaldehydes | 1 | 2013 | 10 | 0.100 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 419 | 0.100 |
Why?
| | Humans | 20 | 2025 | 141187 | 0.100 |
Why?
| | Neoplasms, Experimental | 1 | 2014 | 174 | 0.100 |
Why?
| | Disulfiram | 1 | 2013 | 15 | 0.100 |
Why?
| | Myelodysplastic Syndromes | 1 | 2015 | 142 | 0.100 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2014 | 204 | 0.100 |
Why?
| | Piperazines | 2 | 2007 | 354 | 0.100 |
Why?
| | Adenosine Deaminase | 1 | 2012 | 40 | 0.090 |
Why?
| | Tumor Suppressor Proteins | 1 | 2014 | 325 | 0.090 |
Why?
| | Adaptation, Physiological | 1 | 2016 | 560 | 0.090 |
Why?
| | Colony-Forming Units Assay | 1 | 2011 | 96 | 0.090 |
Why?
| | Enzyme Induction | 1 | 2011 | 90 | 0.090 |
Why?
| | Adipose Tissue | 1 | 2016 | 647 | 0.090 |
Why?
| | Pyrimidines | 2 | 2007 | 477 | 0.090 |
Why?
| | Lymphopenia | 1 | 2011 | 67 | 0.090 |
Why?
| | Cell Culture Techniques | 2 | 2011 | 368 | 0.090 |
Why?
| | Transcription Factors | 2 | 2011 | 1703 | 0.090 |
Why?
| | Cell Count | 1 | 2011 | 326 | 0.090 |
Why?
| | Transplantation, Homologous | 1 | 2012 | 413 | 0.090 |
Why?
| | Mice, Knockout | 3 | 2016 | 3068 | 0.090 |
Why?
| | Aldehydes | 1 | 2011 | 146 | 0.080 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 281 | 0.080 |
Why?
| | Mice, Transgenic | 2 | 2014 | 2180 | 0.080 |
Why?
| | Bone Marrow Transplantation | 1 | 2011 | 294 | 0.080 |
Why?
| | Ethanol | 1 | 2015 | 629 | 0.080 |
Why?
| | Cell Lineage | 1 | 2011 | 350 | 0.080 |
Why?
| | E2F4 Transcription Factor | 1 | 2009 | 8 | 0.080 |
Why?
| | E2F3 Transcription Factor | 1 | 2009 | 10 | 0.080 |
Why?
| | E2F2 Transcription Factor | 1 | 2009 | 15 | 0.080 |
Why?
| | Colorectal Neoplasms | 1 | 2017 | 802 | 0.080 |
Why?
| | E2F1 Transcription Factor | 1 | 2009 | 68 | 0.080 |
Why?
| | Programming Languages | 1 | 2009 | 25 | 0.080 |
Why?
| | Telomerase | 1 | 2011 | 247 | 0.070 |
Why?
| | Cell Line, Tumor | 3 | 2025 | 3469 | 0.070 |
Why?
| | Disease Models, Animal | 2 | 2017 | 4404 | 0.070 |
Why?
| | Database Management Systems | 1 | 2008 | 51 | 0.070 |
Why?
| | Machine Learning | 2 | 2025 | 553 | 0.070 |
Why?
| | Information Storage and Retrieval | 1 | 2009 | 120 | 0.070 |
Why?
| | Lymphoma, B-Cell | 1 | 2009 | 130 | 0.070 |
Why?
| | Telomere | 1 | 2011 | 277 | 0.070 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2007 | 96 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2009 | 162 | 0.070 |
Why?
| | Graft vs Host Disease | 2 | 2007 | 254 | 0.070 |
Why?
| | Antigens, CD34 | 2 | 2023 | 89 | 0.070 |
Why?
| | Rituximab | 2 | 2007 | 204 | 0.070 |
Why?
| | Computer Graphics | 1 | 2007 | 42 | 0.070 |
Why?
| | Lymphocytes | 2 | 2007 | 398 | 0.070 |
Why?
| | Artifacts | 1 | 2007 | 133 | 0.060 |
Why?
| | Guidelines as Topic | 1 | 2008 | 273 | 0.060 |
Why?
| | Granulocyte Colony-Stimulating Factor | 2 | 2007 | 88 | 0.060 |
Why?
| | Gene Expression Regulation | 2 | 2011 | 2599 | 0.060 |
Why?
| | Aphidicolin | 1 | 2004 | 5 | 0.060 |
Why?
| | Apoptosis | 2 | 2004 | 2574 | 0.060 |
Why?
| | Phenanthrolines | 1 | 2004 | 8 | 0.060 |
Why?
| | Topotecan | 1 | 2004 | 13 | 0.060 |
Why?
| | Computational Biology | 1 | 2009 | 661 | 0.050 |
Why?
| | Multienzyme Complexes | 1 | 2003 | 66 | 0.050 |
Why?
| | Cysteine Endopeptidases | 1 | 2003 | 74 | 0.050 |
Why?
| | Hydroxamic Acids | 1 | 2003 | 92 | 0.050 |
Why?
| | Leukapheresis | 1 | 2002 | 26 | 0.050 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2002 | 34 | 0.050 |
Why?
| | Software | 1 | 2007 | 676 | 0.050 |
Why?
| | Muscle Proteins | 1 | 2003 | 240 | 0.050 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2003 | 210 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2007 | 2070 | 0.040 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2002 | 159 | 0.040 |
Why?
| | Immunophenotyping | 3 | 2009 | 329 | 0.040 |
Why?
| | Dendritic Cells | 1 | 2002 | 505 | 0.040 |
Why?
| | Signal Transduction | 1 | 2011 | 5144 | 0.040 |
Why?
| | Forkhead Transcription Factors | 1 | 2019 | 199 | 0.040 |
Why?
| | Aldehyde Dehydrogenase, Mitochondrial | 1 | 2017 | 23 | 0.030 |
Why?
| | Stem Cells | 1 | 2002 | 602 | 0.030 |
Why?
| | Gonads | 1 | 2016 | 23 | 0.030 |
Why?
| | CD36 Antigens | 1 | 2016 | 36 | 0.030 |
Why?
| | Cytoprotection | 1 | 2016 | 57 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2019 | 737 | 0.030 |
Why?
| | Lipolysis | 1 | 2016 | 46 | 0.030 |
Why?
| | Risk Assessment | 1 | 2025 | 3490 | 0.030 |
Why?
| | Disease Progression | 1 | 2023 | 2793 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2002 | 1154 | 0.030 |
Why?
| | Imatinib Mesylate | 2 | 2007 | 80 | 0.030 |
Why?
| | Antigens, CD | 2 | 2009 | 539 | 0.030 |
Why?
| | Tumor Burden | 1 | 2016 | 312 | 0.030 |
Why?
| | Benzamides | 2 | 2007 | 216 | 0.030 |
Why?
| | Genetic Heterogeneity | 1 | 2014 | 58 | 0.030 |
Why?
| | Mice, SCID | 1 | 2014 | 367 | 0.030 |
Why?
| | Half-Life | 1 | 2013 | 146 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2025 | 7856 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2017 | 1737 | 0.020 |
Why?
| | Fatty Acids | 1 | 2016 | 448 | 0.020 |
Why?
| | Adenosine Deaminase Inhibitors | 1 | 2012 | 2 | 0.020 |
Why?
| | Area Under Curve | 1 | 2013 | 324 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2014 | 600 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2016 | 1086 | 0.020 |
Why?
| | Trans-Activators | 1 | 2014 | 388 | 0.020 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2013 | 135 | 0.020 |
Why?
| | Drug Interactions | 1 | 2013 | 406 | 0.020 |
Why?
| | Tamoxifen | 1 | 2012 | 203 | 0.020 |
Why?
| | DNA Primers | 1 | 2012 | 510 | 0.020 |
Why?
| | Female | 5 | 2025 | 75515 | 0.020 |
Why?
| | Transduction, Genetic | 1 | 2011 | 136 | 0.020 |
Why?
| | Protein Engineering | 1 | 2011 | 109 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 987 | 0.020 |
Why?
| | Energy Metabolism | 1 | 2016 | 932 | 0.020 |
Why?
| | Breast Neoplasms | 1 | 2002 | 2250 | 0.020 |
Why?
| | Signaling Lymphocytic Activation Molecule Family Member 1 | 1 | 2009 | 2 | 0.020 |
Why?
| | Phospholipase D | 1 | 2009 | 8 | 0.020 |
Why?
| | rhoB GTP-Binding Protein | 1 | 2009 | 4 | 0.020 |
Why?
| | Leukocyte Common Antigens | 1 | 2009 | 90 | 0.020 |
Why?
| | Base Sequence | 1 | 2012 | 2180 | 0.020 |
Why?
| | von Willebrand Factor | 1 | 2009 | 84 | 0.020 |
Why?
| | Indicators and Reagents | 1 | 2008 | 110 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2022 | 11120 | 0.020 |
Why?
| | Miniaturization | 1 | 2007 | 22 | 0.020 |
Why?
| | Octamer Transcription Factor-1 | 1 | 2007 | 5 | 0.020 |
Why?
| | Interleukin-3 | 1 | 2007 | 24 | 0.020 |
Why?
| | Cell Division | 1 | 2009 | 798 | 0.020 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2007 | 42 | 0.020 |
Why?
| | CD8 Antigens | 1 | 2007 | 75 | 0.020 |
Why?
| | Time | 1 | 2007 | 87 | 0.020 |
Why?
| | Specimen Handling | 1 | 2008 | 182 | 0.020 |
Why?
| | Quality Control | 1 | 2007 | 171 | 0.020 |
Why?
| | CD3 Complex | 1 | 2007 | 106 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 2009 | 397 | 0.020 |
Why?
| | CD4 Antigens | 1 | 2007 | 141 | 0.020 |
Why?
| | Histones | 1 | 2011 | 639 | 0.010 |
Why?
| | Aged | 1 | 2025 | 24574 | 0.010 |
Why?
| | Cluster Analysis | 1 | 2007 | 521 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2007 | 376 | 0.010 |
Why?
| | Inflammation | 1 | 2016 | 2890 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2007 | 429 | 0.010 |
Why?
| | Time Factors | 2 | 2007 | 6956 | 0.010 |
Why?
| | Cell Survival | 1 | 2007 | 1129 | 0.010 |
Why?
| | Middle Aged | 1 | 2025 | 34434 | 0.010 |
Why?
| | Databases, Factual | 1 | 2009 | 1444 | 0.010 |
Why?
| | Cyclins | 1 | 2003 | 92 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2009 | 1431 | 0.010 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2003 | 122 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 2007 | 1150 | 0.010 |
Why?
| | Acetylation | 1 | 2003 | 245 | 0.010 |
Why?
| | Microfilament Proteins | 1 | 2003 | 132 | 0.010 |
Why?
| | Male | 2 | 2025 | 69783 | 0.010 |
Why?
| | Adult | 1 | 2025 | 39177 | 0.010 |
Why?
| | Phosphorylation | 1 | 2007 | 1768 | 0.010 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2003 | 161 | 0.010 |
Why?
| | Nuclear Proteins | 1 | 2007 | 712 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2009 | 1764 | 0.010 |
Why?
| | Pyridones | 1 | 2003 | 176 | 0.010 |
Why?
| | Liver | 1 | 2009 | 1819 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2002 | 417 | 0.010 |
Why?
| | Algorithms | 1 | 2007 | 1763 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2007 | 3348 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2003 | 1242 | 0.010 |
Why?
| | Biomarkers | 1 | 2007 | 4174 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2002 | 2003 | 0.010 |
Why?
| | Phenotype | 1 | 2002 | 3166 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2002 | 2002 | 0.010 |
Why?
|
|
Gasparetto's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|